group. The object oP thIs study has been to assess the influence of an expanded hepatic pool of copper on the incorporation of radioactive copper into caeruloplasmin.
2. Studies with 67CU have shown that radioactivity disappears steadily from the plasma of patients with Wilson's disease for periods up to 296 h. Both in patients with primary biliary cirrhosis and in controls, a well-marked secondary rise occurs as radioactive copper is incorporated into caeruloplasmin.
3. Caeruloplasmin has been isolated from the serum of one control subject, one patient with primary biliary cirrhosis and one with Wilson's disease. Of the plasma radioactivity 90 %was present in the caeruloplasmin of the control subject and the patient with primary biliary cirrhosis; only 27% was found in the caeruloplasmin of the patient with Wilson's disease.
4. Turnover time for liver copper has been determined; in the control subjects it was of the order of 20-30 days, in the patients with primary biliary cirrhosis it was between 600 and 700 days, in Wilson's disease the time exceeded 1800 days. In all cases the turnover time for radioactive copper was significantly less.
5. We conclude (a) that newly arrived radioactive copper is preferentially handled in the presence of copper overload and (b) dilution of radioactive copper in an expanded hepatic pool of the metal cannot alone account for the delayed incorporation found in patients with Wilson's disease.
One of the characteristic findings in patients with Wilson's disease is a deficiency or absence of serum caeruloplasmin (Scheinberg & Gitlin, 1952) . Predictably, studies with radioactive copper ( 64CU) in such patients have shown that there is no incorporation of 64Cu into the serum globulins (Bearn & Kunkel, 1954; Earl, Moulton & Selverstone, 1954) . However, a small number of patients with Wilson's disease have normal or near normal concentrations of caeruloplasmin (Cartwright, Markowitz, Shields & Wintrobe, 1960; Scheinberg & Sternlieb, 1963) . One such patient studied in detail by Sass Kortsak, Cherniak, Geiger & Slater (1959) showed no evidence of incorporation of radioactive copper into the serum caeruloplasmin although the protein was present at a near normal concentration. This finding confirmed the earlier observations of Bush, Mahoney, Markowitz, Gubler, Cartwright &. Wintrobe (1955) and led Sass Kortsak and his colleagues to conclude that the injected 64CU was 'diluted into the tremendously expanded copper pool' and hence was unable to reach the site of protein synthesis.
This type of study cannot be repeated on patients with Wilson's disease once the body stores of copper have been depleted because treatment with penicillamine leads to disappearance of caeruloplasmin from the serum (Walshe, 1968) . Neither can slow catabolism ofcaeruloplasmin by patients with Wilson's disease be accepted as the explanation for delayed incorporation of radioactive copper since the half-life of this protein is apparently normal in such patients (Sternlieb, Morell, Tucker, Green & Scheinberg, 196Ib) . Thus, despite lack of direct proof, the hypothesis of dilution of copper into an expanded body pool of the metal has generally been accepted, presumably because it is inherently reasonable. There is, however, an alternative method of studying the problem; patients with primary biliary cirrhosis have concentrations ofcopper in their livers comparable with those found in the livers of patients with Wilson's disease (Gubler, Brown, Markowitz, Cartwright & Wintrobe, 1957; Hunt, Parr, Taylor & Trott, 1963; Sass Kortsak, 1965; Leeson & Fourman, 1967; Smallwood, Williams, Rosenoer & Sherlock, 1968; Worwood, Taylor & Hunt, 1968) . Thus a study of the handling of radioactive copper by patients with primary biliary cirrhosis should help to clarify the role of an expanded liver pool of copper on the rate of radioactive copper incorporation into caeruloplasmin.
METHODS
The patients with Wilson's disease all fitted the necessary diagnostic criteria, details of which are given in Table 1 . Diagnostic features of the patients with primary biliary cirrhosis are given in Table 2 . The diagnoses and caeruloplasmin concentrations for the other four control subjects can be found in Table 3 .
Studies with radioactive copper were considered to be a necessary part of the investigation of patients with Wilson's disease and of patients referred as possible cases of Wilson's disease; to other subjects the nature and purpose of the studies was explained and their consent was obtained before proceeding further. Owing to the high cost of 67CU, studies with this radioisotope were necessarily limited.
In all cases the dose of radioactivity was less than the maximum suggested by the Radioisotope Advisory Panel of the Medical Research Council. Radioactive copper was given by vein to all patients except P.L. (haemachromatosis) and H.L. (Wilson's disease) who took it by mouth. The techniques used in these radioisotope studies have all been described previously (Osborn & Walshe, 1958 , 1965 Osborn, Roberts & Walshe, 1963) . The ratio of radioactive copper in plasma at 24 h/2 h or 48 h/2 h has been shown to be a measure of the rate of incorporation of copper into caeruloplasmin (Sternlieb, Morell, Bauer, Coombes, De Bobes-Sternberg & Scheinberg, 1961a) ; we have used this estimation for the same purpose. 
The use of 67CU (half-life 61·0 h) has permitted us to determine plasma radioactivity for periods of at least 296 h. On the other hand, 6 4CU (half-life 12·8 h), within the dose limitations observed, can only be determined 'in plasma with reasonable accuracy for 48 h. Serum oxidase activity was determined by the method of Broman (1958) . Oxidase activity was converted into mg of caeruloplasmin/IOO ml by comparison of results with those obtained with purified human caeruloplasmin. However, in the case of patient E.T., owing to the finding of a caeruloplasmin inhibitor in the serum, we assayed the oxidase activity by using the dianisidine reaction on starch-gel blocks (Owen & Smith, 1961) .
Caeruloplasmin was isolated from serum, by using 2 or 3 ml samples applied to DEAEcellulose columns according to the method of Deutsch (1960) . Four fractions were collected: fraction 1 contained the void volume and the bulk of the serum proteins as was demonstrated electrophoretically; fraction 2, washing with 0·5 M-NaCl; fraction 3, caeruloplasmin, identified by its blue colour, oxidase activity and electrophoretic mobility; fraction 4, final washing with 0·5 M-NaCI. With patient E.LL. an extra fraction is recorded in Table 4 since the void volume was collected separately.
Serum copper was measured by a method described by Walshe (1963) and the concentration of copper in liver was determined with sodium diethyl dithiocarbamate after the tissue had been wet ashed with H 2S04 and HCI0 4.
Plasma volumes were calculated from body weight by using the factor given in Documenta Geigy (1962) . Liver mass was estimated from the formula given by Scurry & Field (1943) ; the value so obtained could be checked roughly by comparison with the liver size as delineated by a Picker scintiscanner.
These radiochemical studies together with measurements of the uptake of radioactive copper by the liver and also determinations of the stable copper concentrations in plasma and liver have enabled us to estimate the copper incorporated' daily into caeruloplasmin and the turnover time for copper in the liver via caeruloplasmin. As quantitative data are not available for biliary radioactive copper a correction cannot be made for copper excreted via this route. To make these calculations we have used the following formulae:
Total plasma caeruloplasmin (Cp) = Cp concn. (pg/ml) x plasma vol. (ml) (1) • .
. Total plasma Cp x In 0·5 Dally synthesis of Cp = Half-life of Cp (2) where the half-life of caeruloplasmin is taken as 6 days (Kekki, Koskelo & Nikkila, 1966; Waldman, Morell, Wochner, Strober & Sternlieb, 1967) .
Cu incorporated daily into Cp = Cp synthesis daily x 0'32 x 10-2
where 0·32 % is taken as the copper content of caeruloplasmin (Holmberg & Laurell, 1948 
RESULTS

Plasma 67CU
The plasma concentration of 67CU as a percentage of the dose is shown for patients with Wilson's disease in Fig. 1 . In six of the patients there was a steady decline in plasma radioactivity during the period of study. Included in these was one patient, K.Sz., who had a serum caeruloplasmin concentration of 14 mg/IOO ml (0,373 units). Another patient, S.T., showed a flattening of the curve at 24 h and a slight rise after 120 h; his serum caeruloplasmin concentration at the time of study was 3·5 mg/IOO ml (0,098 units). H.L., who received 67CU bỹ FIG. 1. Plasma radioactive copper ( 6 7CU) levels in seven patients with Wilson's disease expressed as a percentage of dose per litre of plasma periods up to 296 h plotted on a scale using log 3 cyclesx 3 cycles. Patient K.Sz. had 14 mg of serum caeruloplasmin 100 ml at this time. The radioactive copper was given by mouth to patient H.L.; it was given intravenously to all other patients. Patients: T, J.Ba.; 6, D.C.; 0, S.F.;., H.L.;., K.S.; 0, S.T.;., S.W. mouth, achieved a peak plasma concentration at I h but thereafter showed a steady decline in plasma radioactivity until completion of the study at 120 h.
The findings for the three patients with primary biliary cirrhosis and the three control subjects who received 67CU are shown in Fig. 2 . This shows that the findings are different from those in the patients with Wilson's disease.
To take the three control subjects first, patient E.N. with Parkinsonism (serum caeruloplasmin 27 mg/IOO ml, 0·700 units) showed a normal curve; 67CU was cleared rapidly from the plasma, reaching a low point at 2 h and thereafter rising steadily as newly synthesized caeruloplasmin was liberated from the liver. This finding, although greatly extended in time, is in full agreement with earlier published data (Jensen & Kamin, 1957; Sternlieb et al., 1961a; Cartwright & Wintrobe, 1964) . Patient P.G., heterozygous for Wilson's disease (serum caeruloplasmin 18 mg/100 ml, 0·475 units), was also typical of the group he represented (Sternlieb et al., 1961a) in that there was some delay before the secondary rise in plasma radioactivity occurred. The patient with haemachromatosis (p.L., serumcaeruloplasmin 37 mg/100 ml, 0·990 units) received radioactive copper by mouth; absorption was clearly delayed but from 2 h onward the rise in plasma radioactive copper was steady and the angle of slope suggested a
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,," ", " -. rate of caeruloplasmin synthesis slightly faster than in patient E.N., as might have been anticipated from the higher concentration of the protein. By comparison, the patients with primary biliary cirrhosis all showed delayed incorporation of radioactive copper into caeruloplasmin and a greater fall in the plasma concentration before the secondary rise occurred. This was particularly noticeable in patient A.B. However, from 24 h onwards, all showed a steady rise in plasma radioactivity and, in patient E.T., this was shown to be due to the incorporation of radioactive copper into caeruloplasmin by isolation of this protein on a DEAE-cellulose column. Even a simple estimation such as the plasma 24 h/2 hand 48 h/2 h radioactivity ratio clearly shows the difference between the patients with Wilson's disease and the control group, including the patients with primary biliary cirrhosis (Table 3) .
Copper incorporation into caeruloplasmin
Caeruloplasmin was isolated from the plasma of three subjects not less than 24 h after the injection of radioactive copper. Caeruloplasmin was identified by the blue colour and the oxidase activity of the relevant fraction; all fractions were measured for radioactive copper content. The results are shown in Table 4 . The control subject with cirrhosis and a large spontaneous portacaval shunt, G.C., had 90 %of the radioactive copper in a single blue fraction which contained all the oxidase activity recovered. The results for patient E. T. with primary biliary cirrhosis were identical to all intents and purpose. The findings for patient E.LL. with Wilson's disease showed that only 27 %of the plasma radioactivity was present in the caeruloplasmin fraction. The greater part was, in fact, in fraction 2 which contained the serum proteins, less caeruloplasmin. Presumably the radioactivity in this fraction was albumin bound (Beam & Kunkel, 1954) .
Hepatic copper turnover times
Total amounts of stable and radioactive copper in the liver for two control subjects, three patients with primary biliary cirrhosis and three with Wilson's disease are shown in Table 5 . The liver copper was determined chemically in three subjects, D.Ge., with primary biliary cirrhosis, and E.LL. and M.N. with Wilson's disease. As liver biopsy was not indicated for management of the remaining cases and was not justifiable ethically solely for the purpose of this investigation, we estimated the liver copper content from published data; for the control, E.N., with Parkinsonism we took the value of 5 pgjg wet weight (Cumings, 1959; Gubler et al., 1957) ; for patient G.c. with cirrhosis a value of 9·4 pgjg wet weight was taken (Gubler et al., 1957) . For the remaining two patients with primary biliary cirrhosis, E.T. and A.B., we have based our calculations on a liver copper concentration of 220 Jlg/g wet weight, the mean concentration of copper for patients with this disease found by Hunt et al. (1963) and . lower than that found in our other patient with primary biliary cirrhosis, D.Ge., in whom the concentration was 270 Jlg/g wet weight. For patient K.Sz., with presymptomatic Wilson's disease, we took the mean value for hepatic copper found by Sternlieb & Scheinberg (1968) in thirty-one such patients, which, converted into a wet weight basis, gave a value of 192 Jlg/g wet weight.
In our two control subjects, E.N. and G.C., the estimated turnover times for stable copper were 27·5 and 29·3 days respectively, and for radioactive copper 15·3 and 19·0 days, giving a ratio of less than 2: I in each case and suggesting that no great degree of preferential handling of the newly arrived radioactive copper had occurred. In the three cases with primary biliary cirrhosis, the turnover times for stable copper were 616, 603 and 675 days compared with 2954, 1856 and 1836 days in the three patients with Wilson's disease. For radioactive copper the turnover time was 29 days in patient E.T. with primary biliary cirrhosis and 204 days in patient E.LL. with Wilson's disease. The turnover time of stable copper/turnover time of radioactive copper ratio, again indicated preferential handling of the radioactive copper by both cases ( Copper transport in primary biliary cirrhosis was studied by Leeson & Fourman (1967) using radioactive copper. These authors demonstrated a normal graph for plasma radioactivity for 36 h after oral administration of 64CU, presumably secondary to a normal rate of incorporation of copper into caeruloplasmin. However, they did not comment on the significance of this observation from the viewpoint at present under discussion. The purpose of the present investigation has been to determine the effect of an abnormally large hepatic pool of copper on the rate of incorporation of radioactive copper into caeruloplasmin. In primary biliary cirrhosis the enlarged hepatic pool of copper resulted in some delay in the appearance of newly labelled caeruloplasmin in the plasma of our three patients, but after 24 h this proceeded at a normal rate (Fig. 2) . By contrast, all but one (S.T.) of the patients with Wilson's disease, including patient K.Sz. with a near normal concentration of caeruloplasmin, showed a steady fall in the concentration of plasma radioactive copper for periods up to 12 days (Fig. 1) .
The comparison of these two groups of patients has forced us to conclude that the apparent inability of the patients with Wilson's disease to incorporate radioactive copper into caeruloplasmin, even when they are able to synthesize this protein, cannot be explained solely in terms of dilution of the newly injected radioactive copper in an expanded hepatic pool of the metal. This is further confirmed by the finding (Leeson & Fourman, 1967 ) of a normal rate of incorporation of 64CU into caeruloplasmin in primary biliary cirrhosis. Some other mechanism must be sought. Failure of radioactive copper to concentrate in the liver, as may occur in advanced Wilson's disease (Osborn & Walshe, 1967) ,cannot be blamed since, in the present study, calculations have been based on the hepatic concentration of radioactive copper and have not been related to the dose administered. If the report of Needleman, Sahgal & Boshes (1970) that caeruloplasmin in Wilson's disease has an abnormal peptide map proves to be correct, then it is possible that a structurally abnormal protein accepts copper at a rate less than normal.
It is hardly surprising that our calculations show that the larger the hepatic pool of copper the longer is the turnover time for the metal (Table 5 ). The effect is more marked in Wilson's . disease than in primary biliary cirrhosis although the liver pools of copper are of approximately equal size. Despite the longer turnover time, the evidence we have presented strongly supports the hypothesis that the newly arrived metal is preferentially selected by the liver for incorporation into caeruloplasmin. This preferential handling is more marked in primary biliary cirrhosis than in Wilson's disease.
We believe that evidence has not previously been published to show that radioactive copper can be incorporated into caeruloplasmin by patients with Wilson's disease though reference to the work of Bearn & Kunkel (1955, Fig. 2) suggests that, at 20 h, one of their patients did have 64Cu-Iabelled caeruloplasmin in circulation. However, no values were given for caeruloplasmin concentration in this patient so that we have been unable to calculate the rate of incorporation of copper into the protein. The study by Sass Kortsak et al. (1959) showed no evidence of incorporation of radioactive copper into caeruloplasmin by their patient with Wilson's disease who had a normal concentration of the protein. However, as the electrophoretic separation of the serum proteins was carried out only 6 h after administration of the radioisotope, incorporation could hardly have occurred in this time.
Determination of the total serum radioactivity and calculation of the 24 hj2 h or 48 hj2 h ratios can also fail to reveal a slow rate of incorporation as the relatively rapid disappearance of albumin bound radioactive copper more than compensates for the slow rise in globulinbound radioactivity, as in fact occurred in patient E.LL. This mechanism may well have masked slow incorporation of radioactive copper into caeruloplasmin by patient K.Sz. whose fall in plasma radioactivity was very slow after 48 h; delayed incorporation may also account for the late rise in plasma radioactivity observed in patient S.T. though his caeruloplasmin concentration was only 3·5 mg/IOO ml (0'098 units) at the time. Looking at the difference in the handling of radioactive copper by our two groups of patients with hepatic copper overload, those with primary biliary cirrhosis and those with Wilson's disease, it is clear that in the great majority of the latter the rate of caeruloplasmin synthesis was so defective that no valid comparison can be made. However, in a small number of patients with untreated Wilson's disease significant amounts of caeruloplasmin may be found and isolation of this protein on DEAE-cellulose from small plasma samples has made possible a more detailed study of radioactive copper transport mechanisms. Thus, in one case we have been able to show incorporation of radioactive copper into caeruloplasmin, albeit at a decreased rate compared with primary biliary cirrhosis. This suggests that a fundamental difference in the handling of radioactive copper exists between the two groups. The number of results is necessarily limited by the extreme rarity of this type of patient and also by the very considerable expense of 67CU.
The evidence, however limited it may be, leads us to conclude that in primary biliary cirrhosis newly administered copper is not immediately diluted in an enormously expanded liver pool of the metal but is in fact preferentially handled and rapidly made available for caeruloplasmin synthesis. As suggested by Osborn, Szaz & Walshe (1969) this may protect against complete saturation of the hepatic binding sites for copper and widespread copper toxicity. Efficient liver uptake of copper in the face of enormous copper concentrations (from 300 to 1000 Ilg/g wet weight) has been demonstrated in the Dominican variety of Bufo marinus (K. Gibbs & J. M. Walshe, unpublished work). It is apparent therefore that as long as normal mechanisms for handling copper remain intact the metal can be stored away without any damage to essential enzyme systems.
In Wilson's disease the situation is different, the newly arrived copper appears to reach the site of caeruloplasmin synthesis relatively slowly and little radioactivity is found in this protein even when it is present. Thus, in addition to a decreased rate of synthesis of caeruloplasmin much of the metal escapes the 'copper trap' present in the normal liver and is able to diffuse into other tissues, eventually reaching the brain, corneae and kidneys and even copper-vulnerable enzymes in the liver itself, resulting in the classical clinical picture of Wilson's disease.
Addendum added in proof
Since going to press it has been possible to study three further patients; two were siblings of patients with Wilson's disease and one was a young man with abnormalities of posture and movement. The diagnosis of Wilson's disease was established in one sibling (liver copper concentration 63'6Ilg/g wet wt.) ; the other proved to be normal. Caeruloplasmin was isolated from the plasma at 24 h after administration of 64CU and the turnover times for stable and radioactive copper were calculated. The following results were obtained. 
